Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.86 USD | -1.35% | +0.10% | +42.05% |
May. 10 | Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing | MT |
May. 09 | Crinetics Pharmaceuticals Q1 Net Loss Widens | MT |
Financials (USD)
Sales 2024 * | 2.26M | Sales 2025 * | 18M | Capitalization | 3.99B |
---|---|---|---|---|---|
Net income 2024 * | -267M | Net income 2025 * | -294M | EV / Sales 2024 * | 1,439 x |
Net cash position 2024 * | 733M | Net cash position 2025 * | 536M | EV / Sales 2025 * | 192 x |
P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-13.1
x | Employees | 290 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.01% |
Latest transcript on Crinetics Pharmaceuticals, Inc.
1 day | +2.10% | ||
1 week | +0.10% | ||
Current month | +15.34% | ||
1 month | +16.34% | ||
3 months | +37.64% | ||
6 months | +64.41% | ||
Current year | +42.05% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 07-12-31 |
Scott Struthers
FOU | Founder | 62 | 07-12-31 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 15-09-30 |
Matthew Fust
BRD | Director/Board Member | 59 | 18-01-31 |
Director/Board Member | 71 | 20-09-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.02% | 1,487 M€ | +9.21% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 50.54 | +2.10% | 2 913 307 |
24-05-21 | 49.5 | -2.21% | 1,095,179 |
24-05-20 | 50.62 | -1.52% | 713,981 |
24-05-17 | 51.4 | -0.98% | 635,233 |
24-05-16 | 51.91 | +2.81% | 592,865 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.05% | 3.99B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.81% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- CRNX Stock